Squarepoint’s Cytek Biosciences CTKB Stock Holding History

Squarepoint’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-82,776	Closed	-$367K	–	4516
2026 Q2	$367K	Buy	82,776 +57,480	+227%	+$245K	﹤0.01%	3673
2026 Q1	$111K	Buy	+25,296	New	+$119K	﹤0.01%	4049
2025 Q4	–	Sell	-158,641	Closed	-$550K	–	4368
2025 Q3	$550K	Buy	158,641 +13,590	+9%	+$51K	﹤0.01%	3158
2025 Q2	$493K	Buy	145,051 +102,047	+237%	+$340K	﹤0.01%	3294
2025 Q1	$172K	Sell	43,004 -24,911	-37%	-$129K	﹤0.01%	4071
2024 Q4	$441K	Sell	67,915 -42,666	-39%	-$254K	﹤0.01%	3830
2024 Q3	$613K	Sell	110,581 -76,780	-41%	-$435K	﹤0.01%	2952
2024 Q2	$1.05M	Buy	187,361 +170,539	+1,014%	+$1.02M	﹤0.01%	2521
2024 Q1	$113K	Buy	+16,822	New	+$133K	﹤0.01%	3777
2023 Q2	–	Sell	-30,773	Closed	-$283K	–	3632
2023 Q1	$283K	Sell	30,773 -54,660	-64%	-$588K	﹤0.01%	2607
2022 Q4	$872K	Buy	+85,433	New	+$1.15M	﹤0.01%	1915

Other funds holding CTKB

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Squarepoint's CTKB Position: Q3 2026 in Review

Squarepoint sold out of Cytek Biosciences (CTKB) in Q3 2026, closing a stake of 82,776 shares — an estimated $367K sold.

Squarepoint first reported a position in CTKB in Q4 2022 and held it in 11 quarters. The position peaked at $1.05M in Q2 2024. 86 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

Squarepoint reported no remaining Cytek Biosciences position as of Q3 2026 after selling out during the quarter.
Squarepoint sold 82,776 Cytek Biosciences shares in Q3 2026, an estimated $367K.
Squarepoint first reported a position in Cytek Biosciences in Q4 2022 and held it in 11 quarters.
Squarepoint's Cytek Biosciences position peaked at $1.05M in Q2 2024.
86 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.